CLU
0.015
150%
HYT
0.006
-57.1%
WNX
0.115
105.4%
TKM
0.058
-47.3%
ITM
0.053
71%
LML
0.007
-46.2%
AU1
0.034
54.5%
LKO
0.265
-37.6%
MRQ
0.003
50%
ATC
0.002
-33.3%
QEM
0.022
46.7%
OVT
0.002
-33.3%
AQZ
0.83
41.9%
TMX
0.002
-33.3%
ALB
0.056
40%
ARO
0.003
-25%
NFM
0.007
40%
NES
0.003
-25%
SLD
0.6
39.5%
ALU
0.67
-23.9%
SNT
0.035
34.6%
BTN
0.012
-20%
ABE
0.02
33.3%
ENL
0.004
-20%
HIQ
0.008
33.3%
FIN
0.004
-20%
MHM
0.16
33.3%
MAY
0.004
-20%
SMM
0.012
33.3%
PCL
0.008
-20%
WC1
0.016
33.3%
IBR
0.056
-18.8%
FAL
0.55
32.5%
BPG
0.295
-18.1%
MYE
0.53
32.5%
AGE
0.044
-17%
PPK
0.45
32.4%
CD2
0.3
-16.7%
AHK
0.315
31.3%
ZEU
0.005
-16.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Nyrada Inc. (ASX:NYR): Developing NYR-BI03

Nyrada Inc. (ASX:NYR) has made progress on developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke.

– Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.

– Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03.

– Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024

ASX announcement: https://announcements.asx.com.au/asxpdf/20240806/pdf/066by3mf9gs2jy.pdf